Ember LifeSciences announced new strategic investments from Amgen Ventures and TDF Ventures, increasing the company’s total Series A funding to $27 million. The investments follow the company’s previously announced Series A financing led by Sea Court Capital and come as Ember expands commercial availability of its Ember Cube 2 cold chain logistics platform.
Ember LifeSciences is focused on transforming pharmaceutical cold chain logistics through reusable, modular shipping technology that provides real-time monitoring and cloud-based tracking capabilities. The company said the additional funding will support rapid scaling of its logistics platform and further expansion of its global footprint.
The company’s Ember Cube 2 platform was recently recognized with the “Best of the Best” distinction from the Red Dot Award for product design. The platform is designed to improve control and visibility across temperature-sensitive pharmaceutical shipments as the healthcare industry faces growing demand for reliable cold chain distribution for medicines and vaccines.
According to the company, the pharmaceutical cold chain industry experiences billions of dollars in annual losses due to temperature excursions. Ember aims to address those issues with reusable shipping technologies powered by its proprietary temperature control systems.
Ember’s customer and investor base includes companies and organizations such as CVS Health, Cardinal Health, Chartwell, and USADA. The company’s broader product portfolio also includes the original Ember Cube, which received recognition as a 2024 TIME Magazine Invention of the Year and a 2024 Fast Company World Changing Idea.
Ember LifeSciences originated as an offshoot of Ember Technologies, the temperature control consumer brand known for its temperature control mug products. Ember Technologies said its consumer products have generated more than half a billion dollars in total sales to date.
Financial terms of the new strategic investments were not disclosed.
KEY QUOTES:
“Investments from Amgen and TDF Ventures provide us with the deep industry insights needed to scale our logistics platform rapidly. Their investments mark a turning point as we expand our global footprint and bring a new level of precision to healthcare delivery.”
Clay Alexander, Founder And CEO, Ember LifeSciences
